Home › Funds › DME Capital Management, LP › ROIV
DME Capital Management, LP position in ROIV
ROIVANT SCIENCES LTD · Health Care
DME Capital Management, LP reported holding 2,152,669 shares of ROIV (ROIVANT SCIENCES LTD) in its Q2 2026 13F filing — a position valued at US$76.2M, representing 1.95% of its reported portfolio and ranking #18 among its reported holdings. DME Capital Management, LP has disclosed ROIV holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How DME Capital Management, LP's ROIV position evolved
DME Capital Management, LP first disclosed a stake in ROIV in Q1 2024 at 4,190,490 shares (US$44.2M). The position peaked in Q2 2026 at 2,152,669 shares, worth US$76.2M. Across 10 filings, DME Capital Management, LP increased the stake 4 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 2,152,669 shares valued at US$76.2M. Notable position changes include a 50% trim in Q3 2025 (shares rose 43% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 4.19M | $44.17M | New |
| Q2 2024 | 4.81M | $50.85M | Add |
| Q3 2024 | 5.31M | $61.25M | Add |
| Q4 2024 | 5.27M | $62.36M | Reduce |
| Q1 2025 | 5.44M | $54.90M | Add |
| Q2 2025 | 4.55M | $51.29M | Reduce |
| Q3 2025 | 2.28M | $34.43M | Reduce |
| Q4 2025 | 2.07M | $44.90M | Reduce |
| Q1 2026 | 2.15M | $59.63M | Add |
| Q2 2026 | 2.15M | $76.18M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ROIV and 13F data
ROIV (ROIVANT SCIENCES LTD) is a Health Care company. 63 other funds we track also report a position in ROIV — the largest reported positions include QVT Financial LP (US$839.6M), Farallon Capital Management (US$506.4M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$506.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ROIV
- QVT Financial LP 23.72M sh · $839.56M · Q2 2026
- Farallon Capital Management 14.31M sh · $506.40M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 14.31M sh · $506.40M · Q2 2026
- ADAGE CAPITAL PARTNERS GP, L.L.C. 10.35M sh · $366.26M · Q2 2026
- PERCEPTIVE ADVISORS LLC 8.09M sh · $286.14M · Q2 2026
- Patient Square Capital LP 8.02M sh · $283.86M · Q2 2026
- Darwin Global Management, Ltd. 6.75M sh · $234.33M · Q2 2026
- Rubric Capital Management LP 6.00M sh · $212.34M · Q2 2026
- BAKER BROS. ADVISORS LP 4.72M sh · $166.93M · Q2 2026
- Affinity Asset Advisors, LLC 3.75M sh · $132.71M · Q2 2026
- ADAR1 Capital Management, LLC 3.16M sh · $111.73M · Q2 2026
- Maverick Capital 2.83M sh · $100.12M · Q2 2026
More on DME Capital Management, LP
FAQ
How long has DME Capital Management, LP held ROIV?
DME Capital Management, LP has disclosed ROIV holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
What is DME Capital Management, LP's current position in ROIV?
As of Q2 2026, DME Capital Management, LP holds 2.15M shares of ROIV (ROIVANT SCIENCES LTD), valued at $76.18M, representing 1.95% of its reported portfolio and ranking #18.
Has DME Capital Management, LP been buying or selling ROIV?
In the latest 13F filing (Q2 2026), DME Capital Management, LP held unchanged its position in ROIV. The position peaked in Q2 2026 at 2.15M shares.
Which other funds hold ROIV?
Other major institutional holders of ROIV include QVT Financial LP, Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., among 63 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.